External validation of the Simplified PADUA REnal (SPARE) nephrometry system in predicting surgical outcomes after partial nephrectomy

**CURRENT STATUS:** UNDER REVIEW

Chi-Ping Huang  
China Medical University Hospital

Chao-Hsiang Chang  
China Medical University Hospital

Hsi-Chin Wu  
China Medical University Beigang Hospital

Che-Rei Yang  
China Medical University Hospital

Po-Fan Hsieh  
China Medical University Hospital

Guang-Heng Chen  
China Medical University Hsingchu Hospital

Po-Jen Hsiao  
China medical university hospital

Yi-Huei Chang  
China medical university hospital

Yu-Ping Wang  
Taichung Veterans General Hospital

Yu-De Wang  
China Medical University Hospital

d27065@mail.cmuh.org.tw

**Corresponding Author**

**DOI:**

Preprint: Please note that this article has not completed peer review.
SUBJECT AREAS
Urology & Nephrology

KEYWORDS
SPARE system, partial nephrectomy, pentafecta, nephrometry
Abstract

Background

Pentafecta is a major goal in the era of partial nephrectomy (PN). Simplified PADUA REnal (SPARE) nephrometry system was developed to evaluate the complexity of tumor. However, the predictive ability in pentafecta of SPARE system is yet to be determined. The aim of this study was to externally validate the applicability of SPARE nephrometry system in predicting pentafecta achievement after partial nephrectomy, and to examine inter-observer concordance.

Methods

We retrospectively reviewed data of 207 consecutive patients who underwent PN between January 2012 and August 2018 at a tertiary referral center. We obtained SPARE, R.E.N.A.L., and PADUA scores and evaluated correlations among the nephrometries and surgical outcomes including pentafecta by Spearman test. Logistic regression analysis was used to identify independent predictors of pentafecta outcomes. We compared the nephrometries to determine the predictive ability of achieving pentafecta using receiver operating characteristic curve analysis. Fleiss’ generalized kappa was used to assessed interobserver variation in the SPARE system.

Results

Based on the SPARE system, 120, 74, and 13 patients were stratified into low-risk, intermediate-risk, and high-risk groups, respectively. Regarding the individual components of pentafecta, there were significant differences in the complication rate (p=0.03), ischemia time (p<0.001), and percent change of eGFR (p<0.001) among the three risk groups. In addition, higher tumor complexity was significantly associated with a lower achievement rate of pentafecta (p=0.01). In Spearman correlation tests, SPARE nephrometry was correlated with ischemia time (ρ:0.37, p<0.001), operative time (ρ:0.28, p<0.001), complication rate (ρ:0.34, p<0.001), percent change of eGFR (ρ:0.34, p<0.001), and progression of chronic kidney disease stage (ρ:0.17, p=0.02). Multivariate analysis revealed that SPARE significantly affected pentafecta (OR: 0.66, p=0.004). In ROC curve analysis, SPARE showed fair predictive ability in the achievement pentafecta (AUC: 0.73). The predictive ability of pentafecta was similar between nephrometries (SPARE vs. R.E.N.A.L., p=0.92; SPARE vs. PADUA,
p=0.57). The interobserver concordance of SPARE was excellent (Kappa: 0.82, p=0.03).

**Conclusions**

SPARE system was a predictive factor of surgical outcomes after PN. This refined nephrometry had similar predictive abilities for pentafecta achievement compared with R.E.N.A.L. and PADUA.

**Background**

Partial nephrectomy (PN) is the standard of care despite the increased use of surgical approaches for T1 renal tumors and even selected T2 renal tumors[1]. Compared to radical nephrectomy, PN can achieve better renal function preservation without compromising the oncological and overall survival outcomes[2, 3]. Both trifecta and pentafecta remain the major goals in the era of PN[4, 5]. Trifecta is an evaluation of short-term outcomes, and is defined as ischemia time £ 25 minutes, negative surgical margin, and no major complications (defined as a Clavien score of ≥3). Pentafecta is an evaluation of long-term outcomes, that includes all of the criteria of trifecta in addition to including > 90% preservation of estimated glomerular filtration rate (eGFR) and no increase in the stage of chronic kidney disease (CKD) at 1 year after PN. These surgical outcomes are impacted by factors including patient characteristics and tumor complexity[6]. Therefore, standard, reproducible, and precise evaluations of tumor complexity is important in surgical planning and patient counseling.

Several nephrometries have been developed and evaluated, of which the R.E.N.A.L. and PADUA systems are the most widely used and studied[7, 8]. Both R.E.N.A.L. and PADUA have been significant correlated with prolonged ischemia time and post-operative complications, which are the component of trifecta[9]. However, controversy exists with regards to the application of these first generation nephrometries in the prediction of post-operative renal function, which are the component of pentafecta[10, 11]. Only the radius of the tumor and endophytic features are associated with split renal function after PN. Many factors in first generation nephrometries may decrease their predictive ability of functional outcomes[12]. The evolution of surgical techniques and the increasing use of PN may limited the use of the first generation nephrometries. Ficarra et al. proposed a revised version of PADUA, the Simplified PADUA ReNal (SPARE) nephrometry system[13]. The SPARE system is composed of fewer variables, including: 1) rim location; 2) renal sinus involvement; 3) exophytic rate,
and 4) tumor size (Fig. 1). Even though fewer variables are used in the SPARE system, this has not negatively affected the ability to evaluate surgical complexity, and the accuracy to predict overall complications between the original PADUA and SPARE has been shown to be similar[13]. Since the SPARE system is a novel tool, its application and inter-observer concordance have yet to be validated externally. Moreover, few studies have evaluated the predictive ability of pentafecta between the SPARE system and first generation nephrometries. Therefore, the aim of this study was to apply three nephrometries (SPARE, R.E.N.A.L., PADUA) in a contemporary series of PNs in order to externally validate the SPARE system and a perform head-to-head comparisons of the predictive performance.

Methods

Patients and data collection

After Institutional Review Board (IRB) of China Medical University & Hospital approval (CMUH108-REC3-063), 207 consecutive patients who underwent PN via open, laparoscopic or robotic assisted approaches for localized renal tumors between January 2012 and August 2018 at a tertiary referral center were included in this study. All methods were performed in accordance with the relevant guidelines and regulations, and a waiver of informed consent was granted by the IRB. Patients with multiple renal tumors within one kidney, solitary kidney, or recurrent renal cell carcinoma were excluded. Decision of surgical approach and technique of renorrhaphy were determined by the surgeons’ expertise and patients’ preference. All PNs were conducted by the standard renal artery and renal vein on-clamp technique, and conventional resection.

Image study with either abdominal computed tomography (CT) or magnetic resonance imaging (MRI) were obtained from all patients pre-operatively. Warm ischemia was used in LPN and RPN, and cold ischemia was used in OPN. We collected the patients’ demographic and clinical data and imaging studies electronically and analyzed them retrospectively. SPARE, R.E.N.A.L. and PADUA scores were obtained according to the original studies[7, 8, 13]. Based on risk stratification of the SPARE nephrometry, the patients were divided into three groups: low-risk group (score 0-3), intermediate-risk group (score 4-7), and high-risk group (score 8-10). Interobserver concordance of the SPARE
nephrometry was assessed by two urologists and one radiologist (C.G. Heng, P.J. Hsiao, Y.P. Wang), each of whom were blinded to the clinical outcomes. We assessed interobserver variation in the SPARE system according to Fleiss’ generalized kappa.

**Outcome measures**

We collected and analyzed preoperative demographics (gender, age, American Society of Anesthesiologists score, Charlson Comorbidity Index), and perioperative outcomes (operative time, ischemia time, estimated blood loss, complications, length of hospitalization). Complications were defined as surgical-related adverse events within 30 days after surgery, and were assessed using the Clavien-Dindo classification system. A major complication was defined as a Clavien score of ≥ 3. Renal function was assessed by serum Cre and eGFR based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Renal function was assessed by eGFR pre-operatively and 1 year after surgery. Functional change in renal function was displayed in percent change of eGFR (PCE). The following pathology features were recorded: malignancy, subtype of RCC, and surgical margin. Pentafecta were assessed as previously reported[5].

**Statistical analyses**

Categorical variables including sex, positive surgical margin, and achievement of pentafecta are displayed as percentage. And continuous variables are displayed as median (IQR). The Mann-Whitney U-test and Kruskal-Wallis H-test were used to compare two or more nonparametric continuous variables, respectively. The Pearson chi-square test was used to compare categorical variables. Spearman correlation was used to evaluate relationships among SPARE, R.E.N.A.L. and PADUA scores and surgical outcomes. Univariate and multivariate analyses between various clinical features including nephrometries and pentafecta were evaluated using a logistic regression model. The significant factors with a P value threshold of 0.05 in the univariable models were used in subsequent multivariable models. Since three nephrometry scores (SPARE, R.E.N.A.L., and PAUDA) are similar proxy variables for tumor complexity and correlating with each other. Three models were run for predicting each pentafecta. Each model made use of a different scoring system locked into the multivariate logistic regression model. The predictive abilities of the nephrometries
Results
Based on the SPARE system, 120, 74, and 13 patients were stratified into low-risk, intermediate-risk, and high-risk groups, respectively. There were no significant differences among the three groups in baseline characteristics except for tumor size (p<0.001), operative method (p=0.03), and tumor complexity assessed by the three nephrometies (p<0.001) (Table 1). There was a trend that robotic surgery was preferred to the other two operative approaches in the high-risk group. Forty-eight, 52, and 107 patients underwent PN via open, laparoscopic, and robotic approaches respectively, of whom 50% were male. The median (IQR) age was 58 (15) years, the American Society of Anesthesiologists score was 2 (1), the Charlson Comorbidity Index score was 2 (3), and median (IQR) tumor size was 3.5 (1.9) cm.

The median (IQR) operative time was 227 (97) minutes, the ischemia time was 24 (11) minutes, the estimated blood loss was 150 (250) mL, and the length of hospital stay was 8 (2) days (Table 2). Peri-operative outcomes were significantly different in the three risk groups. The patients with a higher tumor risk had the longest operative time (p=0.003) and the longest hospital stay (p=0.02) (Table 2). Clear cell renal cell carcinoma (RCC) (45.9%) was the most common malignant tumor, followed by papillary RCC (8.7%) and chromophobic RCC (8.2%) (Table 2). Regarding the individual components of pentafecta, there were significant differences in the complication rate (p=0.03), ischemia time (p<0.001), and PCE (p<0.001) among the three risk groups. In addition, higher tumor complexity was significantly associated with a lower achievement rate of pentafecta (p=0.01) (Table 2). Spearman correlation analysis showed that the three nephrometry systems were significant correlated with each other (p<0.001) (Table 3). The SPARE system was correlated with ischemia time (p:0.37, p<0.001), operative time (p:0.28, p<0.001), complication rate (p:0.34, p<0.001), length of stay (p:0.18, 0.009), PCE (p:0.34, p<0.001), rate of increase in CKD stage (p:0.17, p=0.02), and rate of achieving pentafecta (p: -0.23, p<0.001). The correlation between peri-operative outcomes and PADUA was similar to the SPARE system, while R.E.N.A.L. was also correlated with EBL (p:0.15, p=0.03) additionally (Table 3).

Univariate analysis showed that sex (OR: 0.32, p=0.04), American Society of Anesthesiologists score
(OR: 0.42, p=0.046), SPARE (OR: 0.66, p=0.003), R.E.N.A.L. (OR: 0.64, p=0.004), and PADUA (OR: 0.64, p=0.003) significantly affected the achievement of pentafecta (Table 4). Multivariable models for achievement of pentafecta using the statistically significant variables from the univariable models are seen in Table 5. Regression analysis showed that all three nephrometries were independent predictive factors of pentafecta in each model (SPARE (OR: 0.66, p=0.004), R.E.N.A.L. (OR: 0.6, p=0.003), PADUA (OR:0.62, p=0.002; Table 5). ROC analysis of pentafecta showed fair predictive ability of the three nephrometries (SPARE (AUC: 0.73), R.E.N.A.L. (AUC: 0.72), PADUA (AUC: 0.75); Fig. 2). The predictive ability of pentafecta was similar between nephrometries (SPARE vs. R.E.N.A.L., p=0.92; SPARE vs. PADUA, p=0.57). The interobserver concordance between two urologists and one radiologist was good in total score (Kappa:0.89, p=0.03), and in each component except for renal sinus involvement (Kappa: 0.69, p=0.05) (Table 6).

Discussion
Achieving trifecta and pentafecta is the major goal of PN regardless of the surgical approach. Therefore, an effective and validated tool to evaluate tumor complexity and surgical difficulty is essential. However, the R.E.N.A.L. and PADUA systems are not without limitations[10, 14]. The SPARE system, a refined version of PADUA, includes tumor size, exophytic rate, sinus involvement and rim location (Fig. 1). Compared to R.E.N.A.L. and PADUA, the SPARE system had similar predictive ability in pentafecta achievement (Fig. 2). In other words, the fewer constituents of the SPARE system did not affect its efficacy while making it easier to calculate the score. Moreover, the interobserver concordance of the SPARE system was good in overall score and in most of the individual components (Table 6). As a result, the SPARE system appears to be a favorable choice when evaluating tumor complexity and predicting post-PN outcomes during clinical practice and patient counseling.

In the current study, SPARE nephrometry affected peri-operative outcomes including ischemia time, operative time, and complication rate. Although there was a trend toward greater functional loss in the higher risk group, Ficarra et al. found that the SPARE system was not associated with functional outcomes[13]. In contrast, the SPARE system was correlated with PCE and pentafecta in our study. This may be due to the different approaches of PN between the two studies. PN was conducted using
standard resection methods in our institute, whereas 25% of the patients in their cohort underwent PN by enucleation[13]. Since resected renal volume plays an important role in functional loss[15], the predictive ability of the SPARE system in functional outcomes may be influenced by the volume of resected non-neoplastic renal parenchyma. In addition, tumor contact surface area has a greater ability to predict post-operative renal function than R.E.N.A.L. and PADUA[11, 16]. SPARE includes components such as radius (R) and exophytic rate (E), which is similar to tumor contact surface area[11]. The other two components of sinus involvement and rim location are related to the vascular territory of the kidneys which affect renal function deterioration[17]. As a result, the SPARE system may be correlated to functional outcomes to some extent. However, further well-designed studies are needed to confirm these hypotheses.

In our study both R.E.N.A.L. and PADUA had good predictive ability for pentafecta achievement. R.E.N.A.L. has been confirmed to be an independent predictive factor of pentafecta achievement with a negative association[18]. In contrast, Ubrig et al. and Harke et al. reported conflicting results about the predictive ability of PADUA for trifecta achievement[19, 20]. The difference regarding the predictive ability of PADUA in pentafecta achievement between studies may be explained by the following reasons. First, there were inconsistencies between studies in controlling for confounding factors such as comorbidities, and patient factors affect post-operative complication rates and functional change[6]. Differences in the methods of multivariate analysis between studies may have resulted in conflicting results. In our study, we included possible factors including age, Charlson Comorbidity Index, BMI, and pre-operative renal function in order to reduce selection bias. Second, unimportant and non-concordant factors in PADUA and a lack of central image review may have led to the difference in results between studies[21].

Our study showed good interobserver concordance with the SPARE system, with a kappa value of 0.82. Hew et al. reported the limited reproducibility of the PADUA score[22], and they reported a Fleiss’ generalized kappa in their study cohort of 0.37 to 0.80 for the various components of the PADUA. Spaliviero et al. directly compared interobserver concordance among R.E.N.A.L., PADUA, and C-index, and found that agreement using the C-index method was higher than with PADUA or
However, limitations existed when scoring the constituents including location and involvement of the collecting system. Therefore, Ficarra et al. refined PADUA into the SPARE system which successfully improved interobserver agreement according to our results. In our cohort, the interobserver concordance of renal sinus involvement was lower and exophytic rate was higher compared with previous studies. This may be because exophytic rate is a semi-quantitative parameter while renal sinus involvement is a qualitative parameter.

To the best of our knowledge, the current study is the first to externally validate the SPARE system. We further confirmed that SPARE is not only a predictive factor in overall complication rate, but also in pentafecta achievement. Besides complication rate, we also found similar predictive abilities of pentafecta achievement between the SPARE and R.E.N.A.L./PADUA systems in ROC analysis. Another strength of the current study is that we provided evidence of the reproducibility of the SPARE system between urologists and radiologist. This result suggests that the SPARE system can be applied across different specialties. However, there are also limitations to this study. First, this is a single center retrospective study design with various confounding factors. However, we tried our best to reduce selection bias by including possible confounding factors which have previously been reported. Second, we lacked unified imaging protocols for CT and MRI because we are a tertiary referral center. Most constituents of the SPARE system are quantitative or semi-quantitative, so there may not have been significant inconsistencies in the scoring. Third, only a small proportion of the patients (6.3%) were classified as being at high risk, which may have limited the findings. Fourth, the PN technique used in the current study was standard resection, so the applicability of SPARE for PN with enucleation is still unclear, and further studies are needed to confirm the efficacy of the SPARE system in high-risk renal tumors and PN with enucleation. Finally, we did not evaluate renal function using radio-isotope scans, which has been proven to be a more precise tool than serum Cre or eGFR, because the aim of this study was to assess pentafecta as defined by a change in renal function as assessed by eGFR. This may not have limited the interpretation of the results.

Conclusions
In conclusion, the results of this study showed that the SPARE system was a predictive factor of
surgical outcomes after PN. This refined nephrometry had similar predictive abilities for pentafecta achievement compared with R.E.N.A.L. and PADUA. The reproducibility, efficacy, and ease of use mean that the SPARE system may replace R.E.N.A.L. and PADUA in clinical practice.

Abbreviations
PN: partial nephrectomy
eGFR: estimated glomerular filtration rates
SPARE: Simplified PADUA REnal nephrometry system
CT: computed tomography
MRI: magnetic resonance imaging
PCE: percent change of ERPF

Declarations

Acknowledgments
The authors would like to thank China Medical University Hospital for providing the opportunity to conduct this study.

Funding
None

Declarations

Ethical Approval and Consent for Publication:
This study was approved by the Ethical Committee of China Medical University Hospital (CMUH108-REC3-063). The study complied with the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations, and a waiver of informed consent was granted by the IRB.

Consent for publication
Not applicable

Availability of data and materials
The data supporting the conclusions are contained within the manuscript. The datasets used and analyzed during the current study are available from the corresponding author on reasonable request
Competing interests

The authors declare that they have no competing interests

Authors’ contributions

CPH designed the study, collected the data, analyzed and interpreted the results, and drafted the manuscript. CHC developed the protocol and collected the data. HCW, CRY, PFH, GHC, PJH, and YHC collected the data and interpreted the result. YDW, YPW analyzed the data. YPW drew the figure. YDW conceived the study, interpreted the data, and reviewed the manuscript. All authors read and approved the final manuscript

References

1. Ljungberg B, Albiges L, Bensalah K, Bex A, Giles RH, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS et al: EAU Guidelines on Renal Cell Carcinoma 2018. In: European Association of Urology Guidelines 2018 Edition. Volume presented at the EAU Annual Congress Copenhagen 2018, edn. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2018.

2. Mir MC, Pavan N, Capitanio U, Antonelli A, Derweesh I, Rodriguez-Faba O, Linares E, Takagi T, Rha KH, Fiori C et al. Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). World J Urol. 2019.

3. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017; 71(4):606-617.

4. Hung AJ, Cai J, Simmons MN, Gill IS. "Trifecta" in partial nephrectomy. J Urol. 2013; 189(1):36-42.

5. Zargar H, Allaf ME, Bhayani S, Stifelman M, Rogers C, Ball MW, Larson J, Marshall S, Kumar R, Kaouk JH. Trifecta and optimal perioperative outcomes of robotic and laparoscopic partial nephrectomy in surgical treatment of small renal masses: a
multi-institutional study. BJU Int. 2015; 116(3):407-414.

6. Cacciamani GE, Gill T, Medina L, Ashrafi A, Winter M, Sotelo R, Artibani W, Gill IS. Impact of Host Factors on Robotic Partial Nephrectomy Outcomes: Comprehensive Systematic Review and Meta-Analysis. J Urol. 2018; 200(4):716-730.

7. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009; 182(3):844-853.

8. Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, Artibani W. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009; 56(5):786-793.

9. Schiavina R, Novara G, Borghesi M, Ficarra V, Ahlawat R, Moon DA, Porpiglia F, Challacombe BJ, Dasgupta P, Brunocilla E et al. PADUA and R.E.N.A.L. nephrometry scores correlate with perioperative outcomes of robot-assisted partial nephrectomy: analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database. BJU Int. 2017; 119(3):456-463.

10. Ficarra V, Crestani A, Bertolo R, Antonelli A, Longo N, Minervini A, Novara G, Simeone C, Carini M, Mirone V et al. Tumour contact surface area as a predictor of postoperative complications and renal function in patients undergoing partial nephrectomy for renal tumours. BJU Int. 2018.

11. Hsieh PF, Wang YD, Huang CP, Wu HC, Yang CR, Chen GH, Chang CH. A Mathematical Method to Calculate Tumor Contact Surface Area: An Effective Parameter to Predict Renal Function after Partial Nephrectomy. J Urol. 2016; 196(1):33-40.

12. Watts KL, Ghosh P, Stein S, Ghavamian R. Predictive Value of Nephrometry Score Constituents on Peri-Operative Outcomes and Individual Renal Function in Patients
Undergoing Minimally Invasive Partial Nephrectomy. Urology. 2016.

13. Ficarra V, Porpiglia F, Crestani A, Minervini A, Antonelli A, Longo N, Novara G, Giannarini G, Fiori C, Simeone C et al. The Simplified PADUA REnal (SPARE) nephrometry system: a novel classification of parenchymal renal tumours suitable for partial nephrectomy. BJU Int. 2019.

14. Khene ZE, Peyronnet B, Kocher NJ, Robyak H, Robert C, Pradere B, Oger E, Kammerer-Jacquet SF, Verhoest G, Rioux-Leclercq N et al. Predicting morbidity after robotic partial nephrectomy: The effect of tumor, environment, and patient-related factors. Urol Oncol. 2018; 36(7):338.e319-338.e326.

15. Klingler MJ, Babitz SK, Kutikov A, Campi R, Hatzichristodoulou G, Sanguedolce F, Brookman-May S, Akdogan B, Capitanio U, Roscigno M et al. Assessment of volume preservation performed before or after partial nephrectomy accurately predicts postoperative renal function: Results from a prospective multicenter study. Urol Oncol. 2019; 37(1):33-39.

16. Wang YD, Huang CP, Chang CH, Wu HC, Yang CR, Wang YP, Hsieh PF. The role of RENAL, PADUA, C-index, CSA nephrometry systems in predicting ipsilateral renal function after partial nephrectomy. BMC Urol. 2019; 19(1):72.

17. Masago T, Yamaguchi N, Iwamoto H, Morizane S, Hikita K, Honda M, Sejima T, Takenaka A. The significance of predictable traumatic area by renorrhaphy in the prediction of postoperative ipsilateral renal function. Cent European J Urol. 2018; 71(1):64-71.

18. Kahn AE, Shumate AM, Ball CT, Thiel DD. Pre-operative factors that predict trifecta and pentafecta in robotic assisted partial nephrectomy. J Robot Surg. 2019.

19. Ubrig B, Roosen A, Wagner C, Trabs G, Schiefelbein F, Witt JH, Schoen G, Harke NN. Tumor complexity and the impact on MIC and trifecta in robot-assisted partial
nephrectomy: a multi-center study of over 500 cases. World J Urol. 2018; 36(5):783-788.

20. Harke NN, Mandel P, Witt JH, Wagner C, Panic A, Boy A, Roosen A, Ubrig B, Schneller A, Schiefelbein F et al. Are there limits of robotic partial nephrectomy? TRIFECTA outcomes of open and robotic partial nephrectomy for completely endophytic renal tumors. J Surg Oncol. 2018; 118(1):206-211.

21. Spaliviero M, Poon BY, Aras O, Di Paolo PL, Guglielmetti GB, Coleman CZ, Karlo CA, Bernstein ML, Sjoberg DD, Russo P et al. Interobserver variability of R.E.N.A.L., PADUA, and centrality index nephrometry score systems. World J Urol. 2015; 33(6):853-858.

22. Hew MN, Baseskioglu B, Barwari K, Axwijk PH, Can C, Horenblas S, Bex A, Rosette JJ, Pes MP. Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. J Urol. 2011; 186(1):42-46.

23. Zargar H, Akca O, Autorino R, Brandao LF, Laydner H, Krishnan J, Samarasekera D, Stein RJ, Kaouk JH. Ipsilateral renal function preservation after robot-assisted partial nephrectomy (RAPN): an objective analysis using mercapto-acetyltriglycine (MAG3) renal scan data and volumetric assessment. BJU Int. 2015; 115(5):787-795.

Tables

Table 1 Demographic information
|                                | Total      | Low risk (0-3) | Intermediate risk |
|--------------------------------|------------|----------------|------------------|
| No.                            | 207        | 120            | 74               |
| Age, years                     | 58(15)     | 58(16)         | 56(17.3)         |
| Male gender                    | 104(50.2)  | 58(48.3)       | 36(48.6)         |
| ASA                            | 2(1)       | 2(1)           | 2(1)             |
| CCI                            | 2(3)       | 3(2)           | 2(3)             |
| BMI, kg/m²                     | 25.6(5.8)  | 26.1(5.9)      | 25.1(5.9)        |
| Hypertension                   | 92(44.4)   | 47(39.2)       | 39(52.7)         |
| Diabetes                       | 32(15.5)   | 19(15.8)       | 11(14.9)         |
| Tumor size, cm                 | 3.5(1.9)   | 3.2(1.6)       | 3.9(2.6)         |
| Operative method               |            |                |                  |
| open                           | 48(23.2)   | 19(15.8)       | 27(36.5)         |
| laparoscopic                   | 52(25.1)   | 35(29.2)       | 15(20.3)         |
| robotic                        | 107(51.7)  | 66(55)         | 32(43.2)         |
| R.E.N.A.L.                     | 7(3)       | 6(2)           | 7(2.5)           |
| PADUA                          | 9(2)       | 8(2)           | 10(2.5)          |
| SPARE                          | 3(4)       | 2(2)           | 5(2.25)          |

*Data are expressed as median (IQR), or n (%)*

*ASA: American Society of Anesthesiologists score, CCI: Charlson Comorbidity Index, BMI: body mass index*

Table 2 Peri-operative outcomes
|                           | Total         | Low risk (0-3) |
|---------------------------|---------------|----------------|
| Ischemia time, minutes    | 24(11)        | 22(10)         |
| Operative time, minutes   | 227(97)       | 210(109)       |
| EBL, mL                   | 150(250)      | 100(250)       |
| Complications             |               |                |
| major, Clavien-Dindo grade 3 or more | 46(22.2) | 26(21.7) |
| minor, Clavien-Dindo grade 2 or less | 8(3.9) | 7(5.8) |
| Length of stay, days      | 8(2)          | 7(3)           |
| PCE                       | 14.9(18.2)    | 11.8(18.8)     |
| CKD upstaging             | 84(40.6)      | 42(35)         |
| Pathological features     |               |                |
| clear cell RCC            | 95(45.9)      | 52(43.3)       |
| papillary RCC             | 18(8.7)       | 10(8.3)        |
| chromophobe RCC           | 17(8.2)       | 7(5.8)         |
| others                    | 7(3.4)        | 3(2.5)         |
| oncocytoma                | 8(3.9)        | 3(2.5)         |
| angiomyolipoma            | 62(30)        | 45(37.5)       |
| Positive surgical margin  | 8(3.9)        | 6(5)           |
| Achievement of pentafecta | 19(9.2)       | 17(14.2)       |

Data are expressed as median (IQR), or n (%)

**EBL**: estimated blood loss, **PCE**: percent change of estimated glomerular filtration rate, **CKD**: chronic kidney disease, **RCC**: renal cell carcinoma

Table 3 Correlation between nephrometries and peri-operative features
### Variables

| Variables                                      | SPARE     | P       | R.E.N.A.L. | P       | Coefficient  |
|------------------------------------------------|-----------|---------|------------|---------|--------------|
| SPARE                                          | 0.61      | <0.001  | 0.79       |         |              |
| R.E.N.A.L.                                     | 0.61      | <0.001  | 0.61       |         |              |
| PADUA                                          | 0.79      | <0.001  | 0.61       | <0.001  |              |
| Ischemia time (minutes)                        | 0.37      | <0.001  | 0.38       | <0.001  | 0.4          |
| Operative time (minutes)                       | 0.28      | <0.001  | 0.23       | <0.001  | 0.25         |
| EBL (mL)                                       | 0.11      | 0.11    | 0.15       | 0.03    | 0.13         |
| Complications (Clavien-Dindo classification)   | 0.34      | <0.001  | 0.22       | 0.002   | 0.28         |
| Length of stay (days)                          | 0.18      | 0.009   | 0.13       | 0.06    | 0.16         |
| PCE (%)                                        | 0.34      | <0.001  | 0.28       | <0.001  | 0.32         |
| CKD upstaging (%)                              | 0.17      | 0.02    | 0.24       | <0.001  | 0.26         |
| Positive margin (%)                            | 0.07      | 0.41    | 0.04       | 0.68    | -0.03        |
| Achievement of pentafecta (%)                  | -0.23     | <0.001  | -0.23      | 0.001   | -0.26        |

**EBL:** estimated blood loss, **PCE:** percent change of estimated glomerular filtration rate, **CKD:** chronic kidney disease

### Table 4 Univariable model of pentafecta

| Variables                                      | OR     | p-value |
|------------------------------------------------|--------|---------|
| Age                                            | 1.02   | 0.37    |
| Sex                                            | 0.32   | 0.04    |
| ASA                                            | 0.42   | 0.046   |
| CCI                                            | 1.22   | 0.06    |
| BMI (kg/m²)                                    | 0.91   | 0.13    |
| Hypertension                                   | 1.78   | 0.1     |
| Diabetes                                       | 0.91   | 0.61    |
| Pre-operative eGFR (ml/min/1.73m²)             | 1      | 1       |
| Operative method                               | 1.15   | 0.64    |
| SPARE                                          | 0.66   | 0.003   |
| R.E.N.A.L.                                     | 0.64   | 0.004   |
| PADUA                                          | 0.64   | 0.003   |
ASA: American Society of Anesthesiologists score, CCI: Charlson Comorbidity Index, BMI: body mass index

Table 5 Multivariable model of pentafecta

|                          | Model including SPARE | Model including RENAL |
|--------------------------|------------------------|-----------------------|
|                          | OR  | p-value | CI      | OR  | p-value |
| Sex                      | 0.35| 0.07    | (0.11, 1.09) | 0.3 | 0.045   |
| ASA                      | 0.25| 0.007   | (0.09, 0.69) | 0.25| 0.007   |
| SPARE                    | 0.66| 0.004   | (0.5, 0.88)  |      |         |
| R.E.N.A.L.               |   |         |         | 0.6 | 0.003   |
| PADUA                    |   |         |         |      |         |

ASA: American Society of Anesthesiologists score,

Table 6 Interobserver concordance of the SPARE and PADUA system

|                                | Kappa | P            |
|--------------------------------|-------|--------------|
| SPARE score                    | 0.89  | 0.03         |
| Tumor size                     | 0.93  | <0.001       |
| Exophytic rate                 | 0.87  | 0.02         |
| Renal sinus involvement        | 0.69  | 0.05         |
| Rim location                   | 0.95  | <0.001       |
| PADUA                          | 0.71  | 0.04         |
| Urinary collecting system      | 0.65  | 0.07         |
| Longitudinal Polar location    | 0.68  | 0.2          |

Figures
SPARE system (A) tumor size classification, (B) tumor deepening into the parenchyma, (C) tumor relationship with renal sinus, (D) margin location of the tumor; This figure is created by YPW.
Figure 2

ROC curve analysis of pentafecta, the predictive ability of pentafecta was similar between nephrometries (SPARE vs. R.E.N.A.L., $p=0.92$; SPARE vs. PADUA, $p=0.57$).